[{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Ashvattha Therapeutics","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ashvattha Therapeutics Announces $69 Million in Series B Financing and up to $45M Exclusive License Agreement with Huadong to Advance Hydroxyl Dendrimer-Based Precision Medicines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"D","amount":"$181.3 million","upfrontCash":"$29.6 million","newsHeadline":"CARsgen, Huadong Medicine Ink Deal To Sell CAR T-cell Product In China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","amount":"$94.2 million","upfrontCash":"$30.0 million","newsHeadline":"Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUADONG MEDICINE Reports Positive Phase I Results for GLP-1 Agonist HDM1002","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Huadong Medicine
HDM1002 is an innovative potent small molecule drug, highly selective full agonist of the GLP-1 receptor. It is being developed for Type 2 Diabetes Mellitus.
Under the collaboration, Huadong will receive license for both the cream and foam formulations of topical Zoryve (roflumilast), a next generation PDE4 inhibitor, for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, and atopic dermatitis.
Under the terms of the exclusive licensing agreement, Huadong will advance research and development costs for Ashvattha’s hydroxyl dendrimer clinical candidates, OP-101, D-4517.2 and OP-801, and for additional preclinical candidates.
CT053 (zevorcabtagene autoleucel), is a fully human, autologous BCMA CAR T-cell product candidate for the treatment of relapsed/refractory multiple myeloma (R/R MM).